Mounjaro's drug class: what type of medicine tirzepatide actually is

You've read 'GLP-1 receptor agonist' on every weight-loss page, so what's different here?

Fair question. Most of the well-known weight-loss injections (including Wegovy and Ozempic) work by mimicking GLP-1, a hormone released after you eat. GLP-1 tells your brain you're full, slows the pace at which food leaves the stomach, and prompts the pancreas to release insulin when blood sugar rises. That's a meaningful intervention. But Mounjaro does something additional.

Tirzepatide also mimics GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone that works alongside GLP-1 in regulating appetite and energy balance. Activating both pathways at once is why tirzepatide gets its own classification: a dual GIP and GLP-1 receptor agonist, and you can read more about how tirzepatide's drug classification is defined and what makes it distinct from single-pathway medicines. The practical consequence, seen in large clinical trials, is a degree of average weight reduction that tends to exceed what single-pathway GLP-1 medicines achieve. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported around 20–21% average body-weight reduction at the 15mg dose over 72 weeks. That figure belongs to the drug class doing two jobs instead of one.

The Mounjaro medicine page covers the full clinical picture if you want to understand what the trial evidence means for real-world use.

The class in context: where tirzepatide sits among weight-loss medicines

Weight-loss medicines span several different drug classes. Orlistat, for instance, is a lipase inhibitor that blocks fat absorption in the gut, a completely different mechanism. GLP-1 receptor agonists arrived later and work centrally on appetite as well as peripherally on digestion. Tirzepatide, as a dual GIP/GLP-1 agonist, is the newest class to be licensed in the UK for weight management, and the page on Mounjaro's class of medication explains how that positioning compares with other licensed options.

Understanding the drug class matters for a couple of practical reasons. First, the side-effect profile follows the mechanism: because both GIP and GLP-1 affect gut motility, the most common effects are gastrointestinal, nausea, loose stools, indigestion and, for some people, constipation. These tend to be most noticeable early in treatment and often ease as the body adjusts. The NHS medicines guidance for tirzepatide lists them in full, alongside what to watch for. Second, the drug class shapes eligibility: Mounjaro's licence covers adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. More on tirzepatide's classification and what it means for eligibility is on the linked page.

NICE recommended tirzepatide for NHS use in December 2024, its technology appraisal TA1026 sets out the qualifying criteria in detail. Private treatment through a regulated pharmacy operates under the licensed eligibility criteria rather than the narrower NHS thresholds.

Black Triangle, prescription-only: what the regulatory status tells you

Mounjaro carries a Black Triangle (▼) designation from the MHRA. This doesn't mean the medicine is unsafe, it means it's newer, and regulators want healthcare professionals and patients to report any suspected side effects promptly, building a larger post-market safety picture. The Yellow Card scheme at yellowcard.mhra.gov.uk is how patients and clinicians report those experiences.

The prescription-only status is the other key regulatory fact. Because tirzepatide is a POM, you can't buy it over a counter or from an online seller without a clinical assessment. That assessment exists to check that the medicine is appropriate for you specifically, your medical history, other medicines, and weight-related conditions all feed into the prescriber's decision. At nume, a GPhC-registered Independent Prescriber reads every consultation the same day; your answers go to a clinician, not a scoring algorithm. If you want to understand what that process involves before you start, our FAQs page covers the common questions.

If you're weighing up whether the dual-agonist class suits your situation better than a single GLP-1 option, a look at the weight-loss treatment overview sets out the landscape plainly. And if cost context matters to you, this page on Mounjaro pricing in the UK explains what private treatment actually includes, worth a read before you compare figures online.

A question our prescribers hear most weeks: does the drug class change who can take it?

Broadly, yes. The drug class determines the licence, and the licence sets the eligibility floor. As a dual GIP/GLP-1 agonist developed specifically for weight management (as well as type 2 diabetes), tirzepatide's licence is different from older medicines in adjacent classes. It's not licensed for children or young people under 18. It isn't recommended during pregnancy, while breastfeeding, or for people who are actively trying to conceive. A personal history of medullary thyroid carcinoma, a family history of that condition, or certain other health circumstances requires careful prescriber review, this is where the clinical assessment does its most important work.

The drug class also matters if you're switching from another medicine. People transferring from a different GLP-1 medicine bring different tolerances and starting points; prescribers at a service like ours review evidence of current treatment before any switch. If you're curious whether tirzepatide's class and profile fit your situation, start a free consultation and a prescriber will work through the detail with you directly.